PrecisionLife CEO, Steve Gardner, will present the keynote lecture at the ALS/MND Natural History Consortium Annual Meeting in Boston.
ALS/MND Natural History Consortium Annual Meeting
February 24-25 | Mass General Brigham, BostonThe ALS/MND Natural History Consortium consists of leading academic medical centers in the U.S. and Europe committed to studying the natural history of ALS and other related motor neuron diseases.
The consortium collaborates with academic ALS centers and pharmaceutical companies to more fully understand the clinical progression of ALS on a large scale, inform better clinical trial design, and encourage development of effective therapies for ALS.
The meeting's keynote will be presented by PrecisionLife CEO, Steve Gardner.
KEYNOTE LECTURE
AI-led Precision Medicine, Drug Repurposing and Rapid Validation Strategies for ALS
Steve Gardner, CEO, PrecisionLife
11:00 - 12:15, Monday 24 February
View the full meeting agenda here.
About PrecisionLife
PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which affect over 5 billion patient lives and account for over 80% of healthcare spending.
The AI-led PrecisionLife platform is unparalleled in its ability to identify causal disease biology – revealing the underlying drivers of many diseases for the first time, linking individuals to the treatments that will benefit them most, and accurately predicting lifetime risk of disease.
PrecisionLife’s precision medicine insights and diagnostic tools hold the key to reducing the global burden of chronic diseases, improving the rate of successful drug development, and increasing healthspan for billions of people.
